ARGENX
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
ARGENX
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2008-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.argenx.com
Total Employee:
501+
Status:
Active
Contact:
833-274-9411.
Email Addresses:
[email protected]
Total Funding:
3.75 B USD
Technology used in webpage:
IPhone / Mobile Compatible Domain Not Resolving SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Common Name Invalid ASP.NET IIS Sectigo SSL
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apeiron Biologics
Apeiron Biologics is a biotech company that focuses on the discovery and development of novel cancer immunotherapies.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Georgiamune
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Oxford BioMedica
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-11-30 | Food and Drug Administration - Priority Review Voucher | Food and Drug Administration - Priority Review Voucher acquired by argenx | 102 M USD |
Investors List
Burrage Capital
Burrage Capital investment in Post-IPO Equity - argenx
MPM Capital
MPM Capital investment in Post-IPO Equity - argenx
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - argenx
Aquila Capital
Aquila Capital investment in Post-IPO Equity - argenx
Erasmus MC Biomedical Fund
Erasmus MC Biomedical Fund investment in Series B - argenx
PMV
PMV investment in Series B - argenx
Omnes Capital
Omnes Capital investment in Series B - argenx
Seventure Partners
Seventure Partners investment in Series B - argenx
OrbiMed
OrbiMed investment in Series B - argenx
Forbion Capital Partners
Forbion Capital Partners investment in Series B - argenx
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-22 | OncoVerity | argenx investment in Series A - OncoVerity | 30 M USD |
| 2019-02-06 | Halozyme Therapeutics | argenx investment in Post-IPO Equity - Halozyme Therapeutics | 30 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2023-03-02 | argenx Announces Planned Transition of Chief Operating Officer |
Official Site Inspections
http://www.argenx.com Semrush global rank: 674.59 K Semrush visits lastest month: 46.44 K
- Host name: 151.101.3.10
- IP address: 151.101.3.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "argenx"
About - One Team, One Culture, One Purpose - Argenx
Luc Truyen is the Chief Medical Officer of argenx and joined the company in 2021. Previously, Luc was with the Johnson & Johnson organization for over 20 years holding various leadership positions, primarily within neuroscience. He …See details»
Company Profile - argenx Annual Report 2023
On May 5, 2017, we transferred the legal ownership of all intellectual property rights of argenx SE to argenx BV, effective retroactively as of January 1, 2017. As a result, since January 1, 2017, (i) argenx BV holds all legal and economic …See details»
Our Commitment to Patients - Argenx
Argenx is committed to improving the lives of people suffering from severe autoimmune diseases. We aim to do this in partnership; by listening to patients, supporters and advocacy communities and hearing your stories. It is your …See details»
Organization and Operations - argenx Annual Report 2022
Risk Factors Related to argenx’s Organization and Operations Our Future Growth and Ability to Compete Depends on Retaining our Key Personnel and Recruiting Additional Qualified …See details»
Company Profile - argenx Annual Report 2022
Argenx was founded on April 25, 2008 and is registered with the trade register of the Dutch Chamber of Commerce under number 24435214. Our registered office is at Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands. Our …See details»
argenx | Governance
Argenx has a one-tier board consisting of executive and non-executive directors, and an executive management team responsible for the day-to-day operations of the company. Board of …See details»
argenx - Crunchbase Company Profile & Funding
Argenx reported strong Q2 sales, which reinvigorated its clinical plans for Vyvgart. The company received a second US approval for Vyvgart Hytrulo in the autoimmune disease CIDP. Argenx also announced its 'Vision 2030' initiative, …See details»
Medical Affairs - argenx Medical
Welcome to Medical Affairs at argenx. Our mission is to continuously improve patient care by driving medical innovation, transformative evidence generation, industry unique collaboration …See details»
Annual Report 2023 | argenx – Home
Read the entire argenx Annual Report 2023 online – the financial year, corporate governance, patient stories and much more. Annual Report 2023 Menu Search. Annual Report 2023. Menu. ... And, as we execute on our ambitious business …See details»
argenx - LinkedIn
Argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology ...See details»
argenx | argenx announces pipeline expansion and “argenx 2021” …
May 21, 2019 As we strive to become a commercial organization, it is this R&D engine that is a key success differentiator of argenx, having allowed us to repeatedly identify first-in-class …See details»
General - argenx Annual Report 2022
General We have a one-tier board structure consisting of one executive director and eight non-executive directors (as of December 31, 2022), and a senior management team (consisting of …See details»
Ethics and Responsibility - Argenx
At argenx, we are on a journey together to achieve the unthinkable. We are all working hard to build an integrated immunology company and reach patients. And in doing so, we are …See details»
Founding of argenx
At a time where access to human antibody engineering technology was difficult, our co-founders found opportunity where scientific discovery met a new approach to innovation. Hear from Tim …See details»
Investors - Argenx
4 days ago Our corporate governance structure is designed to empower our senior executives to drive our business goals and create long-term value for our stakeholders, while ensuring …See details»
Our Story - Argenx
Get argenx news and updates right to your inbox. Subscribe. Download assets Get photos, fact sheets, illustrations and more. Download now. Join the team Dare to do more with a thriving …See details»
argenx to Present at Upcoming Investor Conferences
5 days ago argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers …See details»
Annual Report 2022 | argenx – Home
Message to Our Shareholders. Commitment is the word that comes to mind when I look back at 2022 and all that we accomplished as a team. For the first time in our history, we were able to …See details»
Innovation - The Science of Collaboration - Argenx
The Immunology Innovation Program (IIP) is a core business strategy of argenx connecting the specialized insight into disease and target biology of our external scientific and academic …See details»